Tapering Steroids in Nephrotic Syndrome

Initial Treatment and Tapering

• For patients who achieve remission, corticosteroids should be tapered slowly over a total period of up to 6 months after achieving remission, with the specific approach varying by disease type and patient age, as recommended by the Kidney International guidelines 1
• The American Academy of Pediatrics recommends that children with steroid-sensitive nephrotic syndrome should be tapered from daily prednisone at 60 mg/m²/day to alternate-day dosing at 40 mg/m² on alternate days after 4-6 weeks, and then continue alternate-day therapy for 6 weeks, before tapering by 10 mg/m² per week until reaching 5 mg on alternate days 2, 3
• The total treatment duration should be at least 12 weeks, with tapering extending up to 16 weeks, to reduce relapse rates, according to the Kidney International guidelines 2, 3
• Longer initial treatment courses (up to 6 months total) reduce relapse rates compared to shorter courses, even though this means higher cumulative steroid exposure initially, as stated by the Kidney International and American Journal of Kidney Diseases guidelines 1, 4

Relapse Treatment and Tapering

• For infrequent relapses, the Kidney International guidelines recommend giving 60 mg/m²/day until remission, then switching to 40 mg/m² on alternate days for 4 weeks 1, 4
• For frequent relapses or steroid-dependent disease, the Kidney International guidelines recommend giving 60 mg/m²/day until remission, then switching to 40 mg/m² on alternate days for 1 week, and then tapering by 10 mg/m² per week to complete a total of 4 weeks 2, 3

Critical Tapering Considerations

• The American Journal of Kidney Diseases guidelines state that patients who received shorter courses (2 months) had relapse rates of 81% versus 59% with longer courses (6 months), highlighting the importance of gradual tapering 4
• The Kidney International guidelines recommend monitoring urine dipstick daily during the taper phase, as well as blood pressure and potassium levels, and watching for signs of relapse (≥2+ proteinuria for 3 consecutive days or ≥2+ proteinuria with edema) 2, 3
• The Kidney International guidelines suggest considering steroid-sparing agents instead of prolonged tapering if patient develops steroid dependence or significant steroid toxicity, and recommend cyclophosphamide, cyclosporine, or levamisole as alternatives 1, 5

Special Populations

• For steroid-resistant cases, the Kidney International guidelines recommend not continuing tapering steroids beyond 8-16 weeks if no response, and switching to calcineurin inhibitors (cyclosporine 3-5 mg/kg/day or tacrolimus 0.05-0.1 mg/kg/day) with low-dose corticosteroids 5, 6

Steroid Treatment Guidelines for Nephrotic Syndrome

Initial Treatment

• The American Journal of Kidney Diseases recommends starting prednisone at 60 mg/m²/day (or 2 mg/kg/day, maximum 60 mg) as a single daily dose for 4-6 weeks, followed by 40 mg/m²/dose (or 1.5 mg/kg, maximum 40 mg) on alternate days for 2-5 months with gradual tapering, for a total treatment duration of at least 12 weeks 7, 8
• The initial daily phase dose is 60 mg/m²/day OR 2 mg/kg/day (maximum 60 mg/day) for 4-6 weeks 7, 8, 9
• The alternate-day phase dose is 40 mg/m²/dose OR 1.5 mg/kg/dose (maximum 40 mg on alternate days) for 2-5 months 7, 8, 9

Relapse Treatment

• For infrequent relapses, the daily phase dose is 60 mg/m²/day (maximum 60 mg) until remission achieved (urine dipstick trace/negative for 3 consecutive days) 7, 8, 9
• For frequent relapses or steroid-dependent disease, the daily phase dose is 60 mg/m²/day until remission (3 consecutive days) 7, 8, 9

Important Clinical Considerations

• Children under 1 year should not use standard protocols and should be managed differently with kidney biopsy before treatment 8
• Children over 12 years should consider kidney biopsy before initiating therapy as secondary causes become more common 9
• Steroid resistance is defined as no remission after 8 weeks of appropriate therapy 9

Dose Adjustments and Monitoring

• Prednisone does not require dose adjustment based on GFR levels, even in advanced CKD 10, 11
• Standard dosing is maintained even when GFR <50 mL/min 10, 11
• Monitoring parameters include serum creatinine and GFR, proteinuria (daily urine dipstick), potassium levels, and blood pressure 9, 10, 11

Corticosteroid Treatment Protocol for Adult Primary Nephrotic Syndrome

Initiation & Dosing

• Initiate prednisone at 1 mg/kg/day (maximum 80 mg) or 2 mg/kg on alternate days (maximum 120 mg) for adults with primary nephrotic syndrome; maintain high‑dose therapy for at least 4 weeks and up to 16 weeks until complete remission, then taper slowly over a total 6‑month course【12】【13】.
• Both daily (1 mg/kg/day) and alternate‑day (2 mg/kg) regimens are equally effective, with daily dosing being the most commonly used in practice【14】.

High‑Dose Phase

Minimum & Maximum Duration

• Minimum high‑dose duration: 4 weeks even if remission occurs earlier【12】【13】【15】.
• Maximum high‑dose duration: Do not exceed 16 weeks【12】【13】【14】.

Early Response & Toxicity

• Most responders show a reduction in proteinuria within 4–8 weeks【12】.
• If no response by 8–12 weeks and significant steroid toxicity develops, switch to calcineurin inhibitors (CNIs) rather than continuing high‑dose steroids【12】.

Tapering Phase

Timing of Taper

• Rapid responders: Begin taper 2 weeks after achieving complete remission【14】.
• Slower responders (partial remission at 8–12 weeks): Continue high‑dose therapy up to 16 weeks before tapering【12】.

Taper Schedule & Total Duration

• Reduce prednisone by 5 mg every 1–2 weeks【12】.
• The entire treatment course (high‑dose + taper) should last 6 months【12】【13】【15】.

Disease‑Specific Considerations

Focal Segmental Glomerulosclerosis (FSGS)

• Use the same prednisone dosing as for minimal change disease【12】【13】.
• If no response by 8–12 weeks, strongly consider switching to CNIs【12】.

Alternative First‑Line Therapy (Calcineurin Inhibitors)

Indications for Initial CNI Use

• Consider CNIs as first‑line in patients with uncontrolled diabetes mellitus, severe psychiatric conditions, or severe osteoporosis【12】【13】【14】【15】.

CNI Dosing & Duration

• Continue the chosen CNI for at least 4–6 months before declaring treatment failure【12】.
• When using a CNI, add low‑dose prednisone (≈0.15 mg/kg/day)【12】.

Monitoring & Response Definitions

Complete Remission

• Defined as proteinuria <200 mg/g (<20 mg/mmol) or trace/negative dipstick for 3 consecutive days【12】.
• Achieving complete remission predicts excellent long‑term kidney survival【14】.

Partial Remission

• ≥50 % reduction in proteinuria from baseline【12】.
• If only partial remission is present at 16 weeks, proceed with taper and consider adding a CNI【12】.

Steroid Resistance

• Defined as no remission after 8–16 weeks of adequate corticosteroid therapy; switch to a CNI‑based regimen【12】.

Critical Pitfalls & Safety

• Do not stop steroids before 4 weeks even if remission occurs earlier; early cessation raises relapse risk【13】【15】.
• Do not exceed 16 weeks of high‑dose steroids without response; toxicity outweighs benefit【12】【13】【14】.
• Do not exceed 80 mg/day (or 120 mg on alternate days); higher doses do not improve response but markedly increase toxicity【12】【13】.
• Prolonged high‑dose therapy markedly raises the risk of severe complications (infection, avascular necrosis, new‑onset diabetes, psychiatric effects)【12】.
• Monitor for early signs of steroid toxicity to allow timely transition to alternative agents【12】.

Management of Relapses

Infrequent Relapses

• Retreat with the same initial regimen: prednisone 1 mg/kg/day until remission (minimum 3 days proteinuria‑free)【13】.
• Then switch to 40 mg/m² (≈1.5 mg/kg) on alternate days for at least 4 weeks【13】.

Frequent Relapses / Steroid Dependence

• Avoid repeated high‑dose steroid courses due to cumulative toxicity【14】.
• Transition to steroid‑sparing agents such as rituximab, cyclophosphamide (2–2.5 mg/kg/day for 8 weeks), or CNIs【14】.
• If steroids are continued, use the lowest dose possible on an alternate‑day schedule to maintain remission【13】.

Prednisone Use in Non‑Dialysis CKD Patients

Pharmacokinetic Rationale

Standard Dosing Recommendations

Monitoring Requirements in CKD

Disease‑Specific Protocols

Nephrotic Syndrome in CKD

Membranous Nephropathy in CKD

Alternative Immunosuppressive Strategies

Considerations for Other Immunosuppressants